[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,697,446
  • Shares Outstanding, K 82,258
  • Annual Sales, $ 39,210 K
  • Annual Income, $ -311,350 K
  • EBIT $ -359 M
  • EBITDA $ -360 M
  • 60-Month Beta 2.06
  • Price/Sales 170.89
  • Price/Cash Flow N/A
  • Price/Book 4.35

Options Overview Details

View History
  • Implied Volatility 60.60% (+2.49%)
  • Historical Volatility 34.29%
  • IV Percentile 29%
  • IV Rank 12.93%
  • IV High 153.30% on 12/05/25
  • IV Low 46.82% on 08/18/25
  • Expected Move (DTE 16) 10.58 (13.49%)
  • Put/Call Vol Ratio 2.18
  • Today's Volume 124
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 1.97
  • Today's Open Interest 1,933
  • Open Int (30-Day) 2,509
  • Expected Range 67.89 to 89.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 10
  • High Estimate $-0.38
  • Low Estimate $-1.05
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.87 +2.08%
on 05/19/26
89.46 -12.28%
on 05/11/26
-2.24 (-2.78%)
since 05/01/26
3-Month
73.31 +7.04%
on 03/24/26
91.00 -13.77%
on 03/02/26
-12.88 (-14.10%)
since 02/27/26
52-Week
36.65 +114.11%
on 08/11/25
103.00 -23.82%
on 12/08/25
+48.83 (+164.74%)
since 05/30/25

Most Recent Stories

More News
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data

Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ...

KYMR : 78.47 (-3.62%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

NEW YORK , May 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders.  The investigation...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics Reports Tomorrow After Telling Everyone Exactly When for a Week Straight

Barchart Research What to Expect from KYMR Earnings KYMR Generated April 29, 2026 Current Price $81.51 EPS Estimate $$-0.89 Consensus Rating Strong Buy Average Move 4.38% Kymera Therapeutics Reports Tomorrow...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 78.47 (-3.62%)
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast...

KYMR : 78.47 (-3.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 83.90
2nd Resistance Point 82.30
1st Resistance Point 80.39
Last Price 78.47
1st Support Level 76.88
2nd Support Level 75.28
3rd Support Level 73.37

See More

52-Week High 103.00
Last Price 78.47
Fibonacci 61.8% 77.65
Fibonacci 50% 69.82
Fibonacci 38.2% 62.00
52-Week Low 36.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.